Sana Biotechnology, Inc. (NASDAQ:SANA) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Sana Biotechnology, Inc. (NASDAQ:SANA) has received an average recommendation of “Moderate Buy” from the five ratings firms that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $14.00.

SANA has been the subject of a number of research analyst reports. TD Cowen raised Sana Biotechnology from a “hold” rating to a “buy” rating in a research report on Wednesday, January 8th. HC Wainwright raised their price objective on Sana Biotechnology from $8.00 to $11.00 and gave the company a “buy” rating in a research note on Wednesday, January 8th. Finally, Jefferies Financial Group started coverage on Sana Biotechnology in a research report on Friday. They set a “buy” rating and a $7.00 target price on the stock.

Sana Biotechnology Trading Down 9.2 %

SANA opened at $2.65 on Friday. The company has a fifty day moving average price of $3.00 and a two-hundred day moving average price of $3.31. Sana Biotechnology has a 1-year low of $1.52 and a 1-year high of $10.50. The company has a market cap of $591.66 million, a P/E ratio of -1.89 and a beta of 1.63.

Insider Buying and Selling at Sana Biotechnology

In other news, insider Fmr Llc sold 290,912 shares of the company’s stock in a transaction on Wednesday, January 8th. The shares were sold at an average price of $6.49, for a total value of $1,888,018.88. Following the completion of the sale, the insider now owns 4,541,511 shares in the company, valued at $29,474,406.39. This represents a 6.02 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 31.10% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in SANA. Wilmington Savings Fund Society FSB purchased a new stake in Sana Biotechnology in the 3rd quarter valued at about $29,000. Stifel Financial Corp bought a new position in shares of Sana Biotechnology in the third quarter valued at approximately $43,000. EP Wealth Advisors LLC purchased a new stake in shares of Sana Biotechnology during the third quarter valued at approximately $45,000. Tower Research Capital LLC TRC lifted its holdings in Sana Biotechnology by 229.9% during the fourth quarter. Tower Research Capital LLC TRC now owns 15,136 shares of the company’s stock worth $25,000 after acquiring an additional 10,548 shares during the period. Finally, Cerity Partners LLC purchased a new position in Sana Biotechnology in the fourth quarter worth $25,000. 88.23% of the stock is owned by institutional investors.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.